[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-tumor":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,63,76,107,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":43,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100053479","phase-1-novel-indenoisoquinolone-cmyctopoisomerase-1-inhibitor-lmp744-in-recurrent-glioblastoma-100053479",false,"NCT07416188","Novel Indenoisoquinolone CMYC\u002FTOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","Phase 1\u002FPhase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC\u002FTOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma","* INCLUSION CRITERIA:\n\nParticipant must meet all the following inclusion criteria to be deemed eligible for this study:\n\n* Participants \\>= 18 years of age\n* Tissue-based diagnosis of recurrent glioblastoma, IDH-wildtype by a neuropathologist\n* Karnofsky Performance Status (KPS) \\>60\n* Willing to use effective birth control method\n\n  --The effects of LMP744 on developing human fetuses are unknown. Therefore, females of childbearing potential and their male partners must be willing to use an effective method of contraception during the clinical study (hormonal, barrier, surgical, or abstinence) before study enrollment and for 6 months after the last dose of the study drug. If the female becomes pregnant or suspects she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Agreeable to undergo craniotomy for brain biopsy and\u002For resection\n\n  --Initial diagnostic biopsy under 03-N-0164 to confirm recurrent disease and obtain pre-treatment tissue. Only participants who were not expected to able to achieve a gross total resection of tumor will be included in the study.\n* Willing and able to appoint a durable power of attorney\n* Able to provide informed consent or have a legally authorized representative (LAR) to provide consent, if incapacitated.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n* Pregnant and\u002For nursing females\n\n  --As LMP744 is a novel agent with the potential for teratogenic or abortifacient effects, pregnant and\u002For nursing females will be excluded from receiving drug\n* Significant medical co-morbidities that would compromise the participant s ability to tolerate LMP744 and which cannot reasonably be controlled (per the investigator s judgment, such as poorly controlled chronic kidney disease and\u002For poorly controlled congestive heart failure)\n* Social situations that would limit compliance with study requirements, such as chronic homelessness\n* Prior chemotherapy or biologic therapy completed within 4 weeks (6 weeks for nitrosoureas and mitomycin C) or a duration of 5 half-lives (whichever is shorter)\n* Additional malignancy diagnosed or requiring active treatment within 1 year of screening\n* Unable to undergo an MRI scan of the brain\n* Active autoimmune disease that requires systemic treatment within 2 years of screening\n* Cardiac disease\n\n  * \\>=2 MIs\n  * \\>=2 coronary revascularization procedures\n  * Cardiac Troponin T or I \\>= 2x the institutional upper limit of normal at screening\n  * Ejection fraction \\\u003C45% on screening echocardiogram\n* Chronic hypokalemia (K\\\u003C2.5 mmol\u002FL)\n* Human Immunodeficiency Virus (HIV)\n\n  * Known history of HIV\n  * Positive HIV 1\u002F2 at screening.\n* Active Hepatitis B or Hepatitis C infection at screening\n* Active infection requiring systemic antibacterial, antiviral or antifungal therapy \\\u003C7 days prior to initiation of study drug\n* Recipient of autologous or allogeneic T cells\n* Solid organ or tissue transplant recipients","ALL","18 Years","99 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Background:\n\nGlioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatment and is often fatal. Researchers want to know if a study drug (LMP744) can kill glioblastoma tumor cells.\n\nObjective:\n\nTo test LMP744 in people with glioblastoma.\n\nEligibility:\n\nPeople aged 18 years or older with glioblastoma that returned after treatment.\n\nDesign:\n\nParticipants will be screened. They will have a surgery to remove a small sample of tumor tissue (biopsy) from the brain. This will be done under protocol 03-N-0164. They will stay in the clinic for 1 night. They will also have imaging scans and tests of their heart function.\n\nParticipants will have a central line installed: A flexible tube will be inserted into a vein in the chest. It will be attached to a port under the skin. This port will be used to draw blood and give medicines without having to insert new needles into a vein.\n\nLMP744 will be given through the central line for 5 days in a row. Participants will remain in the clinic for this time.\n\nParticipants will then have a second surgery to remove as much of their tumor as possible. They will remain in the clinic until they recover from the surgery. Then they will recover at home after surgery.\n\nParticipants will return to the clinic to receive the study drug for 5 days in a row through the central line, once a month for up to 12 months. Blood tests, heart function tests, and periodic imaging scans will be repeated during these visits.\n\nParticipants will continue to have telehealth visits every 3 months after they stop taking the drug.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],"Recurrent Glioblastoma","Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype","Relapsed Cancer","Recurrent Tumor","Glioblastoma Multiforme","Recurring Glioblastoma","Brain and Central Nervous System Tumors","Glioma","Glioblastomas","Grade IV Astrocytoma","GBM","Recurrent Glioma (Glioblastoma Multiforme)","High Grade Glioma","Glioma, Malignant","Brain Cancer",[28,35,44,45,46,47,48,49,42],"Neoplasms","Neoplasms, Nerve Tissue","Neoplasms by Histological Type","Glioblastoma Multiforme (GBM)","Phase I","Phase II","RECRUITING","2026-07-10",{"date":53,"type":54},"2026-07-13","ACTUAL",{"date":56,"type":21},"2026-07-16",{"date":58,"type":21},"2032-12-31",{"name":60,"class":61},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",1,{"id":64,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":65,"targetDuration":4,"studyType":22,"phases":66,"briefSummary":26,"conditions":67,"keywords":68,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":75,"locationsCount":62},"100624942",{"count":20,"type":21},[24,25],[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42],[28,35,44,45,46,47,48,49,42],"2026-07-01",{"date":71,"type":54},"2026-07-02",{"date":73,"type":21},"2026-07-07",{"date":58,"type":21},{"name":60,"class":61},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100448857","remaster-recurrent-brain-metastases-after-srs-trial-100448857","NCT05124912","REMASTer: REcurrent Brain Metastases After SRS Trial","Inclusion Criteria:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Patients with radiographically proven (by gadolinium-enhanced \\[Gd-\\] MRI) parenchymal brain metastases from histologically confirmed non-central nervous system (CNS) cancer.\n2. Patients with a \"targetable\", bidimensionally-measurable, intracranial lesion that is radiographically recurrent after previous treatment with SRS +\u002F- surgery (craniotomy or LITT). To classify a lesion as radiographically progressive, the lesion must demonstrate a ≥ 25% increase in size following treatment based on the Neuro-Oncology Criteria of Tumor Response for CNS Tumors. To be \"targetable\" for this study, the lesion should be coverable through a planned single LITT trajectory and thus have a maximum perpendicular diameter (perpendicular to the laser trajectory) of 3 cm. An intra-operative decision to utilize two trajectories is acceptable and patient may remain on study.\n3. Patient must be at least 3 months post initial SRS treatment of the target lesion\n4. Target lesion must be amenable to undergo surgical biopsy and LITT treatment as determined by the treating neurosurgeon.\n5. Frozen pathology diagnosis must be attainable.\n6. Patient must be symptomatically stable for a minimum of 3 days prior to the procedure date on a on a max total daily steroid dose equivalent to 4mg of Dexamethasone.\n7. ≥18 years of age\n8. KPS ≥70\n9. Patient is able and willing to complete study requirements\n10. Patients with adequate hematologic parameters (all tests to be performed within \\\u003C4 weeks of biopsy):\n\n    1. ANC ≥ 1.5 X 109\u002FL\n    2. Platelet count ≥ 100 x 109\u002FL\n11. Blood chemistry laboratory value for serum creatinine \\\u003C 1.5 x ULN (test to be performed within \\\u003C4 weeks of biopsy)\n12. Female patients must have a negative serum pregnancy test at screening. (Not applicable to patients with bilateral oophorectomy and\u002For hysterectomy or to those patients who are postmenopausal)\n13. All patients of reproductive potential must agree to use an effective method of contraception during the study\n14. Patients must be accessible for follow-up\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Patients with greater than 3 progressing lesions at time of enrollment. To classify as a radiographically progressive, lesion must demonstrate a ≥ 25% increase in size following treatment based on the RANO criteria. Of note, there is no exclusion for total number of metastases. However, only one lesion can be selected to be the targeted lesion and this lesion alone may be ablated during the study procedure.\n2. Patients with concomitant newly diagnosed intracranial metastases (concurrent with the targetable radiographically progressive lesion), as these will require prioritized and different treatment approaches.\n3. Prior bevacizumab use within 4 weeks of study initiation\n4. Patients with additional concurrent malignancies requiring active treatment, except non-melanoma skin cancer, or in-situ cancer of the cervix\n5. Patients with a serious active infection or other serious underlying medical conditions that would impair the ability of the patient to complete the protocol related QOL questionnaires and cognition assessments\n6. Inability to tolerate or contraindication to steroid therapy (i.e., dexamethasone)\n7. Deemed ineligible or unable to tolerate SRS therapy by treating neurosurgeon and\u002For radiation oncologist\n8. Patients with any condition that would prohibit them from undergoing a surgical procedure, at the discretion of the treating physician team\n9. Patients unwilling or unable to give consent for participation\n10. Patients unable to comply with study requirements\n11. Patients with diffuse leptomeningeal disease\n12. Patients with rapidly progressing extracranial disease",{"count":83,"type":21},261,[85],"NA","Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.",[88,89,31,90],"Brain Metastases","Radiation Necrosis","Recurrent Metastases",[92,93,94,95,89,88],"Laser Interstitial Thermal Therapy","Stereotactic Radiosurgry","LITT","SRS","2026-06-17",{"date":98,"type":54},"2026-06-18",{"date":100,"type":54},"2022-05-10",{"date":102,"type":21},"2028-10",{"name":104,"class":105},"Monteris Medical","INDUSTRY",9,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":62},"100562954","donafenib-as-adjuvant-therapy-following-ablation-for-recurrent-hcc-100562954","NCT06609876","Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC","Thermal Ablation Combined With Low-dose Donafinib for Early Recurrent Hepatocellular Carcinoma: a Multicenter Prospective Study","Inclusion Criteria:\n\n1. were aged 18-75 years;\n2. had recurrent HCC (RHCC) diagnosed by imaging studies, the first or the second RHCC;\n3. RHCC met the Milan criteria, namely single RHCC lesion less than 5 cm in diameter or no more than 3 tumors (each ≤3 cm in diameter);\n4. the early RHCC (recurrent time \\\u003C1 year)\n5. patients were unwilling to undergo repeat hepatectomy or liver transplantation;\n6. had well-preserved liver function, i.e., Child-Pugh class A or B, and prolonged prothrombin time≤5 s;\n7. patients had an Eastern Cooperative Oncology Group performance status score ≤1.\n8. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. were under 18 years or over 75 years of age;\n2. primary HCC;\n3. recurrent HCC beyond Milan criteria;\n4. RHCC with metastasis or macrovascular tumor thrombus","75 Years",{"count":116,"type":21},108,[85],"This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.",[120,121,122,31],"Hepatocellular Carcinoma","Microwave Ablation","Donafenib","2024-12-01",{"date":125,"type":54},"2024-12-03",{"date":127,"type":54},"2024-10-01",{"date":129,"type":21},"2028-10-01",{"name":131,"class":132},"Sun Yat-sen University","OTHER",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":114,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":62},"100473406","microwave-ablation-simultaneously-combined-with-lenavatinib-for-recurrent-hepatocellular-carcinoma-100473406","NCT05444478","Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma","Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma: a Prospective Randomized Controlled Study","Inclusion Criteria:\n\n1. Primary HCC (BCLC 0-B), and the pathological results is hepatocellular carcinoma；\n2. recurrent HCC without any tumor related therapy；\n3. Tumor number ≤3；\n4. Tumor size ≤5cm;\n5. Good performance, KPS≥90；\n6. Age：18-75\n7. Child-Pugh A or B（score of the B level is no more than 7）\n8. Baseline laboratory examinations meet the Criteria： Leukocyte ≥3.0×109\u002FL； Blood platelet ≥75×109\u002FL； Hemoglobin ≥100g\u002FL； ALT、AST ≤ 3 x limit of normal（ULN）； Serum creatinine ≤ 1.5 x ULN； Prothrombin time \\\u003C ULN+4 s；INR \\\u003C 1.5, Albumin ≥30g\u002FL ； Total bilirubin ≤34mmol\u002FL；\n\nExclusion Criteria:\n\n1. disagreeing to receive follow-up observation and participate the clinical study;\n2. Accompanying with a history of other malignancies;\n3. Accompanying with macrovascular invasion such as portal vain tumor thrombus, hepatic vein tumor thrombus;\n4. with extrahepatic metastasis or lymph metastasis;\n5. receiving system therapy such as targeted therapy or immunotherapy;\n6. receiving local therapy such as ablation or TACE;\n7. Any of the following occurred within 12 months of the study: myocardial infarction, severe \u002F unstable angina, coronary artery bypass grafting, congestive heart failure, cerebrovascular accident (including transient ischemic attack), pulmonary embolism; ongoing arrhythmia by NCI-CTCA standard ≥ 2, prolonged QTc interval (450 ms for males, and\\> 470 ms for females;\n8. other serious acute, chronic physiological or mental disorders or abnormal laboratory examination may increase the risk of participation in study treatment or may interfere with the interpretation of study findings or whom the investigator considers not fit;",{"count":141,"type":21},274,[85],"This study intends to evaluate the efficacy and safety of microwave ablation combined lenvatinib simultaneously for recurrent HCC",[120,121,145,146,31],"Liver Cancer","Lenvatinib","2023-11-05",{"date":149,"type":54},"2023-11-07",{"date":151,"type":54},"2022-07-01",{"date":153,"type":21},"2027-07-01",{"name":131,"class":132}]